OnKure, Inc.

BOULDER, CO · Founded 2011 · Biotech · Public

Precision therapeutics targeting tumor microenvironment and immune response in cancer

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · onkuretherapeutics.com

Sector: Biotech
Headquarters: BOULDER, CO
Founded: 2011
Latest Form D: $53.8M, Apr 2023
Total capital: $94.4M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $94.4M; 10 Form D · last Apr 2023; 43 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 7; 33 pending · first 2018; Rank in peer group#213 of 1449

Capital timeline

Latest events

Apr 2023Private capital raisedForm D · SEC · 10th filing$53.8M
Mar 2021Private capital raisedForm D · SEC · 9th filing$29.1M
Aug 2020Private capital raisedForm D · SEC · 8th filing$1M
Apr 2020Private capital raisedForm D · SEC · 7th filing$3.2M
Mar 2020Private capital raisedForm D · SEC · 6th filing$1M
Sep 2019Private capital raisedForm D · SEC · 5th filing$100K
Feb 2018Private capital raisedForm D · SEC · 4th filing$5M
Jul 2015Private capital raisedForm D · SEC · 3rd filing$495K
Jun 2013Private capital raisedForm D · SEC · 2nd filing$600K
Oct 2011Private capital raisedForm D · SEC · 1st filing$100K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#213 · top 15%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Anthony D. PiscopioResearcherExecutive Officer, DirectorLinked by 1 patent
Andrew J. PhillipsDirectorNamed in SEC Form D filings
Donna D. PeakExecutive Officer, DirectorNamed in SEC Form D filings
Duncan M. WalkerExecutive OfficerNamed in SEC Form D filings
Guobao D. ZhaoDirectorNamed in SEC Form D filings
Isaac D. MankeDirectorNamed in SEC Form D filings

Show all 18 people

James M. WinklerExecutive OfficerNamed in SEC Form D filings
Jason M. LeveroneExecutive OfficerNamed in SEC Form D filings
John Michael DeMatteiExecutive OfficerNamed in SEC Form D filings
Joseph D. RomanoDirectorNamed in SEC Form D filings
Keith M. OliviaExecutive OfficerNamed in SEC Form D filings
Ken D. PeakExecutive Officer, DirectorNamed in SEC Form D filings
Micheal D. CarruthersDirectorNamed in SEC Form D filings
Nicholas M. SaccomanoDirectorNamed in SEC Form D filings
R. Michael CarruthersDirectorNamed in SEC Form D filings
Xuedong D. LiuExecutive Officer, DirectorNamed in SEC Form D filings
Zhao D. GuabaoDirectorNamed in SEC Form D filings
Zhao D. GuobaoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 7 granted of 40

Mar 19, 2026PendingIsoquinolones As PI3K InhibitorsUSPTOApplication 19107476
Mar 18, 2025GrantedProcess For The Preparation Of Cyclic DepsipeptidesUSPTOUS 12,252,511
Aug 29, 2023GrantedProcess For The Preparation Of Cyclic DepsipeptidesUSPTOUS 11,739,123

Show all 40 patent records

Isoquinolones As PI3K InhibitorsMar 19, 2026 · Application 19107476Pending
Process For The Preparation Of Cyclic DepsipeptidesMar 18, 2025 · US 12,252,511Granted
Process For The Preparation Of Cyclic DepsipeptidesAug 29, 2023 · US 11,739,123Granted
Benzimidazole Compounds As HDAC6 InhibitorsMay 24, 2022 · US 11,339,150Granted
Thioester Prodrugs Of Macrocycles As Inhibitors Of Histone DeacetylasesJan 20, 2022 · Application 17358656Pending
Thioester Prodrugs Of Macrocycles As Inhibitors Of Histone DeacetylasesDec 21, 2021 · US 11,203,602Granted
Process for the Preparation of Cyclic DepsipeptidesJul 6, 2021 · US 11,053,284Granted
Process For The Preparation Of Cyclic DepsipeptidesJun 23, 2020 · US 10,689,419Granted
Process For The Preparation Of Cyclic DepsipeptidesOct 16, 2018 · US 10,100,089Granted
Quinolizinones As PI3K InhibitorsApplication 63749421Pending
Quinolizinones As PI3K InhibitorsApplication 63728973Pending
BENZOPYRIMIDIN-4(3H)-ONES As PI3K InhibitorsApplication 18871390Pending
Benzopyridinones And Benzopyrimidinones As PI3K InhibitorsApplication 63723919Pending
Compounds Containing Fused Tricyclic Rings As PI3K InhibitorsApplication 63657426Pending
Isoquinolones As PI3K InhibitorsApplication 63572657Pending
Quinolizinones As PI3K InhibitorsApplication 63571644Pending
Benzopyridinones And Benzopyrimidinones As PI3K InhibitorsApplication 63600371Pending
BENZOPYRIMIDIN-4(3H)-ONES As PI3K InhibitorsApplication PCTUS2023034999Pending
BENZOPYRIMIDIN-4(3H)-ONES As PI3K InhibitorsApplication PCTUS2023032852Pending
Hdac Inhibitor OKI-179 For The Treatment Of Cancers Resulting From A Mapk Pathway MutationApplication PCTUS2023032682Pending
Benzopyridinones And Benzopyrimidinones As PI3K InhibitorsApplication 63532175Pending
Isoquinolones As PI3K InhibitorsApplication 63525460Pending
BENZOPYRIMIDIN-4(3H)-ONES As PI3K InhibitorsApplication PCTUS2023024567Pending
Compounds Containing Fused Tricyclic Rings as PI3K InhibitorsApplication 63939646Pending
Compounds Containing Fused Tricyclic Rings as PI3K InhibitorsApplication 63755899Pending
Isoquinolones As PI3K InhibitorsApplication PCTUS2023032033Pending
BENZOPYRIMIDIN-4(3H)-ONES As PI3K InhibitorsApplication 63416025Pending
Hdac Inhibitor OKI-179 For The Treatment Of Cancer Resulting From A Mapk Pathway MutationApplication 63408323Pending
BENZOPYRIMIDIN-4(3H)-ONES As PI3K InhibitorsApplication 63407873Pending
Isoquinolones As PI3K InhibitorsApplication 63404715Pending
BENZOPYRIMIDIN-4(3H)-ONES As PI3K InhibitorsApplication 63350234Pending
Benzimidazole Compounds As HDAC6 InhibitorsApplication PCTUS2020066916Pending
Benzimidazole Compounds as HDAC6 InhibitorsApplication 62954152Pending
Thioester Prodrugs Of Macrocycles As Inhibitors Of Histone DeacetylasesApplication PCTUS2017033316Pending
Process For The Preparation Of Cyclic DepsipeptidesApplication PCTUS2015032590Pending
Field Sequential Color (fsc) Display Apparatus And Method Employing Different Subframe Temporal SpreadingApplication PCTUS2015019460Pending
Hdac Inhibitor OKI-179 In Combination With Binimetinib For The Treatment Of CancerApplication PCTUS2023012909Pending
Quinolizinones As PI3K InhibitorsApplication PCTUS2025057658Pending
Benzopyridinones And Benzopyrimidinones As PI3K InhibitorsApplication PCTUS2025056078Pending
Benzopyridinones And Benzopyrimidinones As PI3K InhibitorsApplication 63894354Pending

SYRACUSE BIOLABS, INC.Similar federal contract value in Biotech · null in contracts
DualitasSimilar federal contract value in Biotech · null in contracts
PROGNOSYS BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
LUMINARY THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Numab TherapeuticsSimilar federal contract value in Biotech · null in contracts
ARTIFICIAL CELL TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.